Organon & Co. (NYSE:OGN) Shares Sold by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC lessened its holdings in Organon & Co. (NYSE:OGN - Free Report) by 54.9% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 43,945 shares of the company's stock after selling 53,572 shares during the period. O Shaughnessy Asset Management LLC's holdings in Organon & Co. were worth $656,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in OGN. Horizon Bancorp Inc. IN lifted its holdings in shares of Organon & Co. by 2,401.5% in the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock worth $25,000 after acquiring an additional 1,585 shares during the last quarter. Millstone Evans Group LLC bought a new stake in Organon & Co. in the fourth quarter worth $29,000. Larson Financial Group LLC boosted its position in Organon & Co. by 345.4% during the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock valued at $33,000 after buying an additional 1,734 shares during the period. Riverview Trust Co boosted its position in Organon & Co. by 117.7% during the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company's stock valued at $36,000 after buying an additional 1,292 shares during the period. Finally, Versant Capital Management Inc grew its stake in shares of Organon & Co. by 92.2% during the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company's stock valued at $41,000 after buying an additional 1,324 shares during the last quarter. Institutional investors own 77.43% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on OGN. Morgan Stanley dropped their price target on shares of Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 9th. TD Cowen upgraded shares of Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. Finally, Barclays reduced their price target on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $20.60.

Remove Ads

Organon & Co. Stock Performance

Shares of Organon & Co. stock traded down $0.11 on Tuesday, hitting $11.20. 490,126 shares of the company's stock were exchanged, compared to its average volume of 2,645,167. Organon & Co. has a 1 year low of $10.94 and a 1 year high of $23.10. The company has a 50-day simple moving average of $14.56 and a 200-day simple moving average of $15.59. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The stock has a market capitalization of $2.89 billion, a PE ratio of 3.36, a PEG ratio of 0.90 and a beta of 0.73.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. As a group, equities analysts anticipate that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were paid a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 10.00%. The ex-dividend date was Monday, February 24th. Organon & Co.'s payout ratio is 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.